在儿科瘤患者中,新的败血症相关的发病率和死亡率
Alicia M Alcamo1,2, Robert B Lindell1,2, Sydney A Sheetz1
1Division of Critical Care Medicine, Department of Anesthesia and Critical Care, Children's Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Frontiers in oncology
|September 12, 2025
概括
患有癌症的患有败血症的儿童在出院后面临着更高的死亡风险或新的健康问题. 这项研究强调了这个脆弱的儿科群体中不良结果的增加.
科学领域:
- 儿科重症监护医学 儿科重症监护医学
- 儿科瘤学 儿科瘤学
- 传染性疾病 传染性疾病
背景情况:
- 败血症是全球儿童死亡的主要原因之一.
- 儿科败血症后的结果,特别是在患有癌症的儿童中,需要进一步定义.
- 针对性干预的确定高风险群体的不良败血症结果对于有针对性的干预至关重要.
研究的目的:
- 为了比较患有癌症和没有癌症的儿童在败血症后在医院出院时死亡或新发病的风险.
- 调查癌症诊断与儿科败血症幸存者的不良结果之间的关联.
主要方法:
- 在重症监护 (TOPICC) 多中心队列研究数据中对三体性结果预测的分析.
- 通过逻辑回归来比较88名患有癌症和败血症的儿童与没有癌症的儿童.
- 综合结局的评估,包括死亡和新发病率 (定义为 ΔFSS 分数>2).
主要成果:
- 患有癌症的儿童死亡率或新发病率明显高 (22.7%与12.1%,p=0.006).
- 在癌症幸存者中,新发病率更频繁 (13.9%对6.9%,p=0.03).
- 在调整后,癌症诊断是死亡或新增残疾的独立预测因素 (aOR 3.71,p<0.001).
结论:
- 患有癌症的儿科败血症患者在出院时经历了更糟糕的结果.
- 癌症诊断独立地与死亡或败血症后新的残疾增加的几率有关.
- 这些发现强调需要对患有癌症和败血症的儿童进行警监测和量身定制的护理.
相关概念视频
01:30Pneumonia III: Complications and Assessment
792
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
792
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
01:22Healthcare Associated Infections II: Preventive Measures
3.6K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.6K
01:28Asepsis
3.1K
The condition of being free from disease-causing living pathogens is asepsis. Aseptic techniques include a set of standard practices to achieve asepsis. An example is the regular environmental cleaning of all parts of the healthcare facility and hand hygiene at home before preparing or eating food. Medical and surgical asepsis in healthcare practice protects patients from harmful pathogens, minimizes the risk of contamination of susceptible sites, and reduces the risk of infection transmission.
3.1K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
258
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
258